Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Exhibit 25.1 Annual Percentage Changes in the Prescription Drug Price Index and Prescription Drug Expenditures, Copyright 2011 Health Administration.

Advertisements

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Estimated annual percentages of new

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Life expectancy at birth in all countries included

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Road to targeting mutant p53

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 5 Palliative-care-referral patterns

Figure 2 Frequency and overlap of alterations

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Variations between planned and delivered doses of radiation

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.31 Figure 4 Spending on hospital care versus spending on prescription drugs Figure 4 | Spending on hospital care versus spending on prescription drugs. a | Percentages of total US health-care spending on hospital-based care versus prescription drugs49. b | Annual profit margins of hospitals versus those of drug manufacturers, as a percentage of total income distribution132. c | Pharmaceutical manufacturers obtain more money in profit, despite a smaller share of total health-care spending. Prasad, V. et al. (2017) The high price of anticancer drugs: origins, implications, barriers, solutions Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.31